Travere Therapeutics, Inc. (TVTX) earnings
TVTX earnings moved a median of +0.04% by the close. Quarterly and annual TVTX reports and results, each read against the price at its own news timestamp. Back to the TVTX overview →
30 measured TVTX earnings events.
Where these TVTX earnings landedvs 30 measured TVTX earnings reactions
| Middle 50% of TVTX earnings reactions | -3.77% to +2.14% |
|---|---|
| Median reaction (to close) | +0.04% |
| Measured reactions | 30 |
Point-in-time · zero look-ahead
Half of the 30 TVTX earnings events with a measured close landed between -3.77% and +2.14%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Travere Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.73% | +1.23% | |
| Travere Therapeutics Reports Second Quarter 2026 Financial Results | Press release | +2.73% | +1.23% | |
| Travere Therapeutics to Report Second Quarter 2026 Financial Results | Press release | -0.60% | -1.65% | |
| Form 10-Q Travere Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.86% | -3.97% | |
| Travere Therapeutics Reports First Quarter 2026 Financial Results | Press release | -1.86% | -3.97% | |
| Travere Therapeutics to Report First Quarter 2026 Financial Results | Press release | +1.41% | -0.20% | |
| Form 10-K Travere Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.04% | +3.09% | |
| Form 10-Q Travere Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.68% | +2.96% | |
| Travere Therapeutics Reports Third Quarter 2025 Financial Results | Press release | -1.68% | +2.96% | |
| Travere Therapeutics to Report Third Quarter 2025 Financial Results | Press release | +0.81% | -1.78% | |
| Form 10-Q Travere Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -8.97% | -2.87% | |
| Travere Therapeutics Reports Second Quarter 2025 Financial Results | Press release | -8.97% | -2.87% | |
| Travere Therapeutics to Report Second Quarter 2025 Financial Results | Press release | +1.48% | +1.71% | |
| Form 10-Q Travere Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.34% | +0.28% | |
| Travere Therapeutics Reports First Quarter 2025 Financial Results | Press release | -3.34% | +0.28% | |
| Travere Therapeutics to Report First Quarter 2025 Financial Results | Press release | +0.93% | +6.01% | |
| Form 10-K Travere Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.54% | +2.23% | |
| Form 10-Q Travere Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.73% | +4.17% | |
| Travere Therapeutics Reports Third Quarter 2024 Financial Results | Press release | +1.73% | +4.17% | |
| Travere Therapeutics to Report Third Quarter 2024 Financial Results | Press release | +0.79% | +0.73% | |
| Form 10-Q Travere Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.50% | -10.18% | |
| Travere Therapeutics Reports Second Quarter 2024 Financial Results | Press release | -2.50% | -10.18% | |
| Travere Therapeutics to Report Second Quarter 2024 Financial Results | Press release | +0.05% | -0.40% | |
| Form 10-Q Travere Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.92% | -8.78% | |
| Travere Therapeutics Reports First Quarter 2024 Financial Results | Press release | -3.92% | -8.78% | |
| Travere Therapeutics to Report First Quarter 2024 Financial Results | Press release | -1.49% | +2.79% | |
| Form 10-K Travere Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -0.98% | +1.84% | |
| Form 10-Q Travere Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -4.56% | -12.45% | |
| Travere Therapeutics Reports Third Quarter 2023 Financial Results | Press release | -4.56% | -12.45% | |
| Travere Therapeutics to Report Third Quarter 2023 Financial Results | Press release | -0.07% | -3.19% |
Keep exploring
More TVTX: analyst actions → · SEC filings → · TVTX overview →